Upregulation of dopamine D2 receptors in dopaminergic drug-naive patients with Parkin gene mutations

Movement Disorders

Volumn 21, Issue 6, 2006, Pages 783-788

  Scherfler, Christoph ^a,d   Khan, Naheed L ^b   Pavese, Nicola ^a   Lees, Andrew J ^c   Quinn, Niall P ^b   Brooks, David J ^a   Piccini, Paola P ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

11C raclopride; 18F dopa; Dopamine D2 receptors; Parkin gene mutation; Parkinson's disease; Positron emission tomography

Indexed keywords

AMANTADINE; APOMORPHINE; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; FLUORINE 18; LEVODOPA; PARKIN; RACLOPRIDE C 11; TRIHEXYPHENIDYL; DOPAMINE RECEPTOR BLOCKING AGENT; RACLOPRIDE; UBIQUITIN PROTEIN LIGASE;

ADULT; AGE; ARTICLE; BINDING KINETICS; BRAIN REGION; CAUDATE NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG SENSITIVITY; FEMALE; GENE MUTATION; HUMAN; MALE; PARKINSONISM; POSITRON EMISSION TOMOGRAPHY; PRESYNAPTIC NERVE; PRIORITY JOURNAL; PUTAMEN; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; TREATMENT OUTCOME; GENE AMPLIFICATION; GENE EXPRESSION REGULATION; GENETICS; MIDDLE AGED; ONSET AGE; PARKINSON DISEASE; PATHOPHYSIOLOGY; POLYMERASE CHAIN REACTION; RADIOGRAPHY; REFERENCE VALUE;

ADULT; AGE OF ONSET; CORPUS STRIATUM; DOPAMINE ANTAGONISTS; GENE AMPLIFICATION; GENE EXPRESSION REGULATION; HUMANS; MIDDLE AGED; PARKINSON DISEASE; POLYMERASE CHAIN REACTION; POSITRON-EMISSION TOMOGRAPHY; RACLOPRIDE; RECEPTORS, DOPAMINE D2; REFERENCE VALUES; UBIQUITIN-PROTEIN LIGASES;

EID: 33745827777     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.20811     Document Type: Article

References (33)

1. Leroy E, Anastasopoulos D, Konitsiotis S, Lavedan C, Polymeropoulos MH. Deletions in the Parkin gene and genetic heterogeneity in a Greek family with early onset Parkinson's disease. Hum Genet 1998;103:424-427.
2. Kitada T, Asakawa S, Hattori N, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998;392:605-608.
3. Abbas N, Lucking CB, Ricard S, et al. A wide variety of mutations in the parkin gone are responsible for autosomal recessive parkinsonism in Europe: French Parkinson's Disease Genetics Study Group and the European Consortium on Genetic Susceptibility in Parkinson's Disease. Hum Mol Genet 1999;8:567-574.
4. Shimura H, Schlossmacher MG, Hattori N, et al. Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease. Science 2001;293:263-269.
5. Van de Warrenburg BP, Lammens M, Lucking CB, et al. Clinical and pathologic abnormalities in a family with parkinsonism and parkin gene mutations. Neurology 2001;56:555-557.
6. Hilker R, Klein C, Ghaemi M, et al. Positron emission tomographic analysis of the nigrostriatal dopaminergic system in familial parkinsonism associated with mutations in the parkin gene. Ann Neurol 2001;49:367-376.
7. Scherfler C, Khan LN, Pavese N, et al. Striatal and cortical pre- and postsynaptic dopaminergic dysfunction in sporadic parkin-linked parkinsonism. Brain 2004;127:1332-1342.
8. 18F]dopa PET and clinical study. Brain 2002;125:2248-2256.
9. Khan NL, Katzenschlager R, Watt H, et al. Olfaction differentiates parkin disease from early-onset parkinsonism and Parkinson disease. Neurology 2004;13:1224-1226.
10. Farde L, Hall H, Ehrin E, Sedvall G. Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. Science 1986;231:258-261.
11. 11C]raclopride. J Cereb Blood Flow Metab 1993;13:310-314.
12. 11C-raclopride. Arch Neurol 1993;50:474-480.
13. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988;51:745-752.
14. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-442.
15. Fahn S, Elton RL. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, editors. Recent developments in Parkinson's disease. Florham Park, NJ: MacMillan Health Care Information; 1987. p 153-163.
16. Lucking CB, Durr A, Bonifati V, et al. Association between early-onset Parkinson's disease and mutations in the parkin gene: French Parkinson's Disease Genetics Study Group. N Engl J Med 2000;342:1560-1567.
17. Spinks TJ, Jones T, Bloomfield PM, et al. Physical characteristics of the ECAT EXACT3D positron tomograph. Phys Med Biol 2000;45:2601-2618.
18. Gunn RN, Lammertsma AA, Hume SP, Cunningham VJ. Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. Neuroimage 1997;6:279-287.
19. Patlak CS, Blasberg RG. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data: generalizations. J Cereb Blood Flow Metab 1985;5:584-590.
20. Friston KJ, Ashburner J, Frith CD, Poline JB, Heather JD, Frackowiak RS. Spatial registration and normalization of images. Hum Brain Mapp 1995;3:165-189.
21. Rinne UK, Laihnen A, Rinne JO, et al. Positron emission tomography demonstrates dopamine D2 receptor supersensitivity in the striatum of patients with early Parkinson's disease. Mov Disord 1990;5:55-59.
22. 11C-raclopride and positron emission tomography. Ann Neurol 1992;31:184-192.
23. 11C]N-Methylspiperone. J Nucl Med 2000;41:65-70.
24. Creese I, Burt DR, Snyder SH. Dopamine receptor binding enhancement accompanies lesion-induced behavioural supersensitiviy. Science 1977;197:596-598.
25. Leenders KH, Aquilonius SM, Bergström K, et al. Unilateral MPTP lesion in a rhesus monkey: effects on the striatal dopaminergic system measured in vivo with PET using various novel tracer. Brain Res 1988;445:61-67.
26. Tedroff J. Parkinson's disease: pathophysiology and PET. Doctoral thesis. Uppsala: Acta Universitatis Upsaliensis; 1990.
27. Perlmutter JS, Kilbourn MR, Raichle ME, Welch MJ. MPTP-induced upregulation of in-vivo dopaminergic radioligands-receptor binding in humans. Neurology 1987;37:1575-1579.
28. Lee T, Seeman P, Rajput A, Farley IJ, Hornykiewicz O. Receptor basis for dopaminergic supersensitivity in Parkinson's disease. Nature 1978;,73:59-61.
29. Guttman M, Seeman P. L-dopa reverses the elevated density of D2 dopamine receptors in Parkinson's diseased striatum. J Neural Transm 1985;64:93-103.
30. Graham WC, Sambrook MA, Crosmann AR. Differential effects of chronic dopaminergic treatment on dopamine D1 and D2 receptors in the monkey brain in MPTP-induced parkinsonism. Brain Res 1993;602:290-303.
31. Reches A, Wagner HR, Jackson-Lewis V, Yablonskaya-Alter E, Fahn S. Chronic levodopa or pergolide administration induces down-regulation of dopamine receptors in denervated striatum. Neurology 1984;34:1208-1212.
32. Jenner P, Boyce S, Marsden CD. Receptor changes during chronic dopaminergic stimulation. J Neural Transm 1998;27(Suppl):161-175.
33. Khan NL, Graham E, Critchley P, et al. Parkin disease: a phenotypic study of a large case series. Brain 2003;126:1279-1292.